Thiogenesis wins FDA rare pediatric disease designation for Leigh syndrome therapy TTI-0102

• Thiogenesis Therapeutics won FDA Rare Pediatric Disease designation for TTI-0102 to treat Leigh syndrome.
• Status could support a Priority Review Voucher if an NDA is approved, creating a potential monetizable asset.
• Company is completing Phase 2 start-up activities for TTI-0102 in Leigh syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thiogenesis Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607130600NEWSFILECNPR____20260713_304821_1) on July 13, 2026, and is solely responsible for the information contained therein.